H.U. Group Holdings, Inc.
MRCHF
Other OTC20.21
USD
+0.70
- -
ISIN
JP3822000000
Return %
Stock
S&P500
1Y
-7.29
26.53
3Y
-0.69
76.60
5Y
-16.83
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Goki Ishikawa
- Full Time Employees
- 5,295
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Shinjuku Mitsui Building Tokyo Japan 163-0408
- IPO Date
- Aug 3, 2012
- Website
- hugp.com
- Similar Companies
- Business
- H.U. Group Holdings, Inc. is a Japan-based company specializing in healthcare services, in vitro diagnostics (IVD), lab testing, and related healthcare support services. The company operates primarily through its four core business segments: Lab Testing and Its Related Services, In-Vitro Diagnostics, Healthcare-related Services, and Research & Development. Within Lab Testing, H.U. Group provides comprehensive clinical laboratory testing including infectious disease, cancer, and lifestyle disease diagnostics with advanced technologies such as chemiluminescence and immunoassays. Its Diagnostics segment manufactures and markets in-vitro diagnostic reagents and instruments. Healthcare-related Services include sterilization services, operating room support, endoscopy room assistance, medical equipment maintenance, logistics management, and nursing care equipment rental and sales. The company targets medical institutions and healthcare providers primarily in Japan and increasingly in international markets through its subsidiaries. Founded in 2014 and headquartered in Tokyo, H.U. Group is focused on creating a healthy society by providing novel, value-added healthcare products and services. Recent strategic developments include the company’s ongoing integration strategy begun in 2022, positioning it as a second founding phase with bold structural reforms for sustainable growth and synergy creation across its operations. In 2019, it acquired Fluxus, Inc. (U.S.) and ADx NeuroSciences N.V. (Belgium), expanding its CDMO (contract development and manufacturing organization) capabilities. Recently, it expanded its neuro testing portfolio with new fully automated assays, reinforcing its research and development efforts. H.U. Group also completed a significant equity buyback in 2025 to enhance shareholder value. Operational reforms include unifying domestic sales structures and strengthening group integration in R&D and sales to enhance profitability in its Lab Testing segment. The company continues to invest in the H.U. Bioness Complex for full-scale operations supporting diagnostics and therapeutics innovation. H.U. Group remains committed to expanding its product portfolio and geographic reach while maintaining regulatory compliance and clinical validation standards essential to its healthcare and diagnostic services.